RET and non-small cell lung carcinoma: LOXO-292 and BLU-667 have been approved since 2020 by the American Food and Drug Administration for the treatment of advanced RET-driven NSCLC, and other potent and selective RET inhibitors, such as BOS17273820 and KL590586 (NCT05265091) are undergoing clinical evaluation.